UPDATE: Leerink Swann Initiates Coverage on Ventrus Bioscience (VTUS) at Outperform, Strong Pipeline
Tweet
Share
E-mailGet Alerts VTUS Hot Sheet
Price: $1.45 --0%
Rating Summary:
3 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 1
Rating Summary:
3 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 1
Join SI Premium – FREE
Leerink Swann initiated coverage on shares of Ventrus Bioscience (Nasdaq: VTUS) with an Outperform rating and a $24-$26 valuation range.
The firm believes that the company's current valuation offers an attractive risk reward scenario given the available clinical data for the compounds and their respective market opportunities.
Leerink Swann noted three during that provide them with confidence in their outlook; VEN 309 for Hemorrhoids is entering its phase III study in early fiscal 2012 and is forecasted to generate $600 million in sales. VEN 307 for anal fissures is anticipated to reach the market by 2014 with peak sales of $55 million in the U.S. VEN 308 for fecal incontinence is also a solid pipeline candidate as the firm estimates peak sales of $75 million for the drug.
The firm released its 2011 and 2012 EPS estimates at a loss of $3.32 and a loss of $2.33.
The firm believes that the company's current valuation offers an attractive risk reward scenario given the available clinical data for the compounds and their respective market opportunities.
Leerink Swann noted three during that provide them with confidence in their outlook; VEN 309 for Hemorrhoids is entering its phase III study in early fiscal 2012 and is forecasted to generate $600 million in sales. VEN 307 for anal fissures is anticipated to reach the market by 2014 with peak sales of $55 million in the U.S. VEN 308 for fecal incontinence is also a solid pipeline candidate as the firm estimates peak sales of $75 million for the drug.
The firm released its 2011 and 2012 EPS estimates at a loss of $3.32 and a loss of $2.33.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canaccord Genuity Starts TMX Group Ltd (X:CN) (TMXXF) at Buy
- Scotiabank Starts Qualys (QLYS) at Sector Perform
- Goldman Sachs Resumes JD.com, Inc (JD) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
